Arecor Therapeutics (LON:AREC) Reaches New 1-Year Low – What’s Next?

Arecor Therapeutics plc (LON:AREC)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as GBX 50 ($0.63) and last traded at GBX 52 ($0.66), with a volume of 3900 shares. The stock had previously closed at GBX 52.50 ($0.67).

Arecor Therapeutics Trading Down 1.0 %

The company has a debt-to-equity ratio of 5.51, a quick ratio of 6.24 and a current ratio of 1.37. The business has a fifty day simple moving average of GBX 62.15 and a 200 day simple moving average of GBX 71.84. The company has a market cap of £19.63 million, a P/E ratio of -1.84 and a beta of -0.18.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.